Today's Information |
Provided by: PharmaEssentia Corp. | |||||
SEQ_NO | 2 | Date of announcement | 2022/08/11 | Time of announcement | 18:09:46 |
Subject | The Board of Directors Approved the Appointment of the Chief Scientific Officer | ||||
Date of events | 2022/08/11 | To which item it meets | paragraph 8 | ||
Statement | 1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer,research and development officer, internal audit officer, or designated and non-designated representatives): Chief Scientific Officer (CSO) 2.Date of occurrence of the change:2022/08/11 3.Name, title, and resume of the previous position holder:N/A 4.Name, title, and resume of the new position holder:Lih-Ling Lin / Chief Scientific Officer / The Head of Checkpoint Immunology Cluster in Immunology and Inflammation Research Area at Sanofi 5.Type of change (please enter: "resignation", "position adjustment", "dismissal", "retirement", "death" or "new replacement"):New appointment 6.Reason for the change:New appointment 7.Effective date:2022/08/01 8.Any other matters that need to be specified: The new appointment of the Chief Scientific Officer was disclosed in the Company's material information on August 1, 2022, and was approved by the Board of Directors on August 11, 2022. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
PharmaEssentia Corporation published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 10:23:04 UTC.